[ad_1]
The injection pen of Eli Lilly and Company’s weight loss drug Zepbound is on display in New York City, the United States, on December 11, 2023.
Brendan McDermid | Reuters
most doses Eli Lilly and CompanyPopular weight loss drug Zepbound and diabetes drug Mounjaro will experience supply shortages in the second quarter of this year as demand surges, according to a company. renew Wednesday’s U.S. Food and Drug Administration drug shortage database.
All doses of Zepbound and Mounjaro are in shortage except for the 2.5 mg version. A Previous updates said some doses of both drugs were in limited supply through April.
A new update shows that insatiable demand for a popular class of weight loss and diabetes drugs continues to be in short supply despite Eli Lilly and its main rivals. Novo Nordiskin an effort to increase the production of these treatments.
Many patients are struggling to find injectable treatments, and the need to help them lose weight has surged over time. These treatments are sometimes called incretin drugs, which mimic gut hormones to suppress appetite and regulate blood sugar.
“We recognize this situation may lead to disruption of people’s treatment regimens and are taking action
“We have purpose, a sense of urgency, and are committed to helping meet the surge in demand,” a spokesperson for Eli Lilly said in a statement to CNBC. The company expects its investments in manufacturing and supply capabilities “to be phased in throughout 2024 and beyond.” Increase the production of our medicines”. Add to.
Eli Lilly said in February that it had achieved its goal of doubling its production capacity for such incretin drugs by the end of 2023. Growth occurs in the second half of 2023.
By that time this year, the company expects to increase production of salable doses of its incretin drug by at least 1.5 times compared with the second half of 2023.
Eli Lilly also said a new plant in Concord, North Carolina, could begin producing the incretin drug as early as the end of this year, with products to be shipped in 2025. facility.
Novo Nordisk announced a similar effort. Some doses of its weight-loss drug Wegovy and diabetes drug Ozempic are also experiencing supply shortages, according to the FDA’s website.
[ad_2]
